High-throughput screening-driven lead discovery: Meeting the challenges of finding new therapeutics

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 4, 2005, Pages 487-494

  Posner, Bruce A ^a  

^a PFIZER INC   (United States)

Author keywords

ADME; High throughput screening; Lead discovery; Medicinal chemistry; Toxicology; Virtual screening

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; GLUTAMATE TRANSPORTER; IMATINIB; LY 487379; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDUSTRY; DRUG METABOLISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; REVIEW; TREATMENT FAILURE;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; MOLECULAR BIOLOGY;

EID: 21444453119     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Hefti E, Bolten B: Advances in high-throughput screening - do they lead to new drugs? Decision Resources Inc, Waltham, MA, USA (2003) March 10. http://www.decisionresources.com/stellent/groups/ public/documents/abstract/ dr_005477.hcsp
2. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Disc (2002) 1(9):727-730.
3. Zambrowicz BP, Sands AT: Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Disc (2003) 2(1):38-51.
4. Outlook 2003: Tufts Center for the Study of Drug Development, Boston, MA, USA (2003). http://csdd.tufts.edu/
5. Bonduelle Y, Pisani J: The future of pharma: Back to basics. PriceWaterhouseCoopers LLP, New York, NY, USA (2003). http://www.pwcglobal.com/ Extweb/pwcpublications.nsf/docid/FD8F8D7D 014FEF2385256DEA0057C302
6. Addressing pharma's R&D productivity crisis: Technological and strategic initiatives to improve core drug discovery capabilities. Datamonitor, New York, NY, USA (2004). http://www.datamonitor. com/ ~2ffff38a506142faae284f03809a4297~/industries/research/?pid=D MHC1960&type=Report
7. Horrobin DF: Modern biomedical research: An internally self-consistent universe with little contact with medical reality? Nat Rev Drug Disc (2003) 2(2):151-154.
8. Walker MJ, Barrett T, Guppy LJ: Functional pharmacology: The drug discovery bottleneck? Drug Disc Today: TARGETS (2004) 3(5):208-215.
9. Williams M: A return to the fundamentals of drug discovery? Curr Opin Invest Drugs (2004) 5(1):29-33.
10. Jorgensen WL: The many roles of computation in drug discovery. Science (2004) 303(5665):1813-1818. Provides a useful overview of the applications of computational chemistry in drug discovery.
11. Fox S, Farr-Jones S, Sopchak L, Boggs A, Comley J: High-throughput screening: Searching for higher productivity. J Biomol Screen (2004) 9(4):354-358.
12. Proudfoot JR: Drugs, leads and drug-likeness: An analysis of some recently launched drugs. Bioorg Med Chem Lett (2002) 12(12):1647-1650. Presents a concise, provocative overview of drugs and their associated leads.
13. Walters WP, Namchuk M: Designing screens: How to make your hits a hit. Nat Rev Drug Disc (2003) 2(4):259-266. Provides a good overview of HTS assay design and associated technologies.
14. Bleicher KH, Bohm HJ, Muller K, Alanine AI: Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Disc (2003) 2(5):369-378.
15. Gribbon P, Andreas S: High-throughput drug discovery: What can we expect from HTS? Drug Disc Today (2005) 10(1):17-22.
16. Lipinski C, Hopkins A: Navigating chemical space for biology and medicine. Nature (2004) 432(7019):855-861.
17. Lipinski CA: Lead- and drug-like compounds: The rule-of-five revolution. Drug Disc Today: Technol (2004) 1(4):337-341. Provides a valuable perspective on how the rule-of-five has impacted - efforts to define drug-like, lead-like and tool-like compounds.
18. MacCoss M, Baillie TA: Organic chemistry in drug discovery. Science (2004) 303(5665):1810-1813. Presents an insightful discussion of the changes taking place in the role of organic chemistry in drug discovery.
19. Copeland RA: Mechanistic considerations in high-throughput screening. Anal Biochem (2003) 320(1):1-12. Provides a valuable reference for mechanistic considerations in HTS assay design.
20. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. Science (2002) 298(5600):1912-1934.
21. Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME: Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett (2005) 15(3):761-764.
22. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, Jones RE, Kahana JA, Kral AM, Leander K, Lee LL, Malinowski J: Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J (2005) 385(Pt 2):399-408.
23. Noble ME, Endicott JA, Johnson LN: Protein kinase inhibitors: Insights into drug design from structure. Science (2004) 303(5665):1800-1805.
24. Parang K, Sun G: Design strategies for protein kinase inhibitors. Curr Opin Drug Discovery Dev (2004) 7(5):617-629.
25. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 2(5):561-566.
26. Druker BJ, Lydon NB: Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 105(1):3-7.
27. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 56(1):100-104.
28. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT et al: Structures of human MAP kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol (2004) 11(12):1192-1197.
29. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 5(7):810-816.
30. Sebolt-Leopold JS: Development of anticancer drugs targeting the MAP kinase pathway. Oncogene (2000) 19(56):6594-6599.
31. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA (1995) 92(17):7686-7689.
32. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Disc (2002) 1(4):309-315. An interesting historical perspective on protein kinases as drug targets.
33. Lu Z, Yin Z, James L, Syto R, Stafford JM, Koseoglu S, Mayhood T, Myers J, Windsor W, Kirschmeier P, Samatar AA et al: Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase. J Biomol Screen (2004) 9(4):309-321.
34. Groom CR, Hopkins AL: Protein kinase drugs - optimism doesn't wait on facts. Drug Disc Today (2002) 7(15):801 -802.
35. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD: Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Disc (2005) 4(2):131-144. A detailed discussion of the potential of the metabotropic glutamate receptors as drug targets for neurological diseases.
36. May LT, Christopoulos A: Allosteric modulators of G protein-coupled receptors. Curr Opin Pharmacol (2003) 3(5):551 -556.
37. Christopoulos A: Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat Rev Drug Disc (2002) 1(3):198-210.
38. Lindsley CW, Wisnoski DD, Leister WH, O'Brien JA, Lemaire W, Williams DL Jr, Bumo M, Sur C, Kinney GG, Pettibone DJ, Tiller PR et al: Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem (2004) 47(24):5825-5828.
39. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD: Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: Synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine. J Med Chem (2003) 46(15):3189-3192.
40. Chin DN, Chuaqui CE, Singh J: Integration of virtual screening into the drug discovery process. Mini Rev Med Chem (2004) 4(10):1053-1065.
41. Olah MM, Bologa CG, Oprea TI: Strategies for compound selection. Curr Drug Disc Technol (2004) 1(3):211-220.
42. Oprea TI, Matter H: Integrating virtual screening in lead discovery. Curr Opin Chem Biol (2004) 8(4):349-358.
43. Alvarez JC: High-throughput docking as a source of novel drug leads. Curr Opin Chem Biol (2004) 8(4):365-370.
44. Jain AN: Virtual screening in lead discovery and optimization. Curr Opin Drug Discovery Dev (2004) 7(4):396-403.
45. Laird ER, Blake JF: Structure-based generation of viable leads from small combinatorial libraries. Curr Opin Drug Discovery Dev (2004) 7(3):354-359.
46. Rishton GM: Nonleadlikeness and leadlikeness in biochemical screening. Drug Disc Today (2003) 8(2):86-96.
47. Rishton GM: Reactive compounds and in vitro false positives in HTS. Drug Disc Today(1997) 2(9):382-384.
48. Nicolaou CA, Tamura SY, Kelley BP, Bassett SI, Nutt RF: Analysis of large screening data sets via adaptively grown phylogenetic-like trees. J Chem Inf Comput Sci (2002) 42(5):1069-1079.
49. McGovern SL, Caselli E, Grigorieff N, Shoichet BK: A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem (2002) 45(8):1712-1722.
50. McGovern SL, Shoichet BK: Kinase inhibitors: Not just for kinases anymore. J Med Chem (2003) 46(8):1478-1483.
51. Nassar A-E, Kamel AM, Clairmont C: Improving the decision-making process in the structural modification of drug candidates: Enhancing metabolic stability. Drug Disc Today (2004) 9(23):1020-1028.
52. Nassar A-E, Kamel AM, Clarimont C: Improving the decision-making process in structural modification of drug candidates: Reducing toxicity. Drug Disc Today (2004) 9(24):1055-1064.
53. Beresford AP, Segall M, Tarbit MH: In silico prediction of ADME properties: Are we making progress? Curr Opin Drug Discovery Dev (2004) 7(1):36-42. Review of progress in computational approaches to ADME properties and their integration into the drug discovery process.
54. Butcher EC, Berg EL, Kunkel EJ: Systems biology in drug discovery. Nat Biotechnol (2004) 22(10):1253-1259.
55. Hood L, Perlmutter R: The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol (2004) 22(10):1215-1217. An interesting prospectus on the role of systems biology in drug discovery.